Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...
Detailed price information for Roche Holding Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in ...
There has recently been speculation that Alteogen is exposed to the risk of being chased by latecomers such as Samsung ...
The Patents Court has dismissed an application by Merck Sharp & Dohme (UK) Limited seeking further disclosure of experimental ...
Temporary Suspension of KOSPI Transfer Listing...Background of Staying Attracts Attention While Alteogen has faced share ...
3don MSNOpinion
The patent cliff could cost billions: How Bayer and Merck & Co. respond—and how Vidac Pharma is gaining momentum
Bayer Fights on Several Fronts Under the leadership of Bill Anderson, the Leverkusen-based Bayer Group is facing a ...
Tech Times on MSN
Space cancer therapy and chip research end with Expedition 74 crew return this weekend
Expedition 74 crew return this weekend ends eight months of ISS research into cancer drug delivery nanoparticles and ...
Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results